The UK-based ProtecT trial reports that, after a median of 10 years of follow up, there is no significant difference in prostate cancer–specific mortality between active monitoring, surgery, and radiotherapy. However, the likelihood of developing metastases is more than twice as great with active monitoring compared with treatment.
http://ift.tt/2gX2Q6T
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου